UPDATE: Edwards Lifesciences (EW) Posts Q3 EPS of 58c; Sees FY12 Revs at Low-End of Range, Guides 4
(Updated - October 19, 2012 4:05 PM EDT)
Edwards Lifesciences Corp. (NYSE: EW) reported Q3 EPS of $0.58, versus the analyst estimate of $0.56. Revenue for the quarter came in at $447.9 million versus the consensus estimate of $476.56 million.
Edwards Lifesciences Corp. sees Q4 2012 revenue of $490-520 million, versus the consensus of $504.8 million.
Sees FY12 sales at bottom-end of $1.90 billion to $1.97 billion range.
For earnings history and earnings-related data on Edwards Lifesciences Corp. (EW) click here.
Edwards Lifesciences Corp. (NYSE: EW) reported Q3 EPS of $0.58, versus the analyst estimate of $0.56. Revenue for the quarter came in at $447.9 million versus the consensus estimate of $476.56 million.
Edwards Lifesciences Corp. sees Q4 2012 revenue of $490-520 million, versus the consensus of $504.8 million.
Sees FY12 sales at bottom-end of $1.90 billion to $1.97 billion range.
For earnings history and earnings-related data on Edwards Lifesciences Corp. (EW) click here.